Cipla Limited — Efavirenz Exporter Profile
Indian Pharmaceutical Exporter · #3 for Efavirenz · $3.0M export value · DGFT Verified
Cipla Limited is the #3 Indian exporter of Efavirenz with $3.0M in export value and 59 verified shipments. Cipla Limited holds a 5.4% market share in Efavirenz exports across 12 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Efavirenz Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Efavirenz?
| Country | Value | Shipments | Share |
|---|---|---|---|
| COLOMBIA | $618.6K | 13 | 29.1% |
| MYANMAR | $373.0K | 10 | 17.6% |
| UNITED STATES | $256.4K | 6 | 12.1% |
| ALGERIA | $245.9K | 6 | 11.6% |
| BELARUS | $150.0K | 3 | 7.1% |
| MALAYSIA | $103.7K | 8 | 4.9% |
| THAILAND | $103.6K | 6 | 4.9% |
| LIBYA | $100.0K | 2 | 4.7% |
| ZAMBIA | $63.5K | 2 | 3.0% |
| GAUTEMALA | $50.0K | 1 | 2.4% |
Cipla Limited exports Efavirenz to 12 countries. The largest destination is COLOMBIA accounting for 29.1% of Cipla Limited's Efavirenz shipments, followed by MYANMAR (17.6%) and UNITED STATES (12.1%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Efavirenz from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CIPLA COLOMBIA SAS Y/O DEPOSITO UPS | COLOMBIA | $318.6K | 7 |
| CIPLA USA INC UPS SUPPLY CHAIN SOLU | UNITED STATES | $221.5K | 5 |
| JDS CO, LTD, | MYANMAR | $203.6K | 8 |
| CIPLA COLOMBIA SAS Y/O DEPOSITO UP | COLOMBIA | $200.0K | 4 |
| STATE ENTERPRISE ACADEMPHARM | BELARUS | $150.0K | 3 |
| PHARMACIE CENTRALE DES HOPITAUX PCH | ALGERIA | $145.9K | 4 |
| CIPLA MALAYSIA SDN BHD | MALAYSIA | $103.7K | 8 |
| JDS CO., LTD | MYANMAR | $101.2K | 4 |
| CIPLA COLOMBIA SAS Y O DEPOSITO UPS | COLOMBIA | $100.0K | 2 |
| TO THE ORDER OF NATIONAL CERTER FOR | LIBYA | $100.0K | 2 |
Cipla Limited supplies Efavirenz to 20 buyers globally. The largest buyer is CIPLA COLOMBIA SAS Y/O DEPOSITO UPS (COLOMBIA), followed by CIPLA USA INC UPS SUPPLY CHAIN SOLU (UNITED STATES) and JDS CO, LTD, (MYANMAR). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Efavirenz Export Value and How Much Does Cipla Limited Contribute?
India exported $26.7M worth of Efavirenz through 1,084 shipments from 101 suppliers to 121 countries, serving 361 buyers globally. Cipla Limited contributes $3.0M to this total, accounting for 5.4% of India's Efavirenz exports. Cipla Limited ships Efavirenz to 12 countries through 20 buyers.
What Is the Average Shipment Value for Cipla Limited's Efavirenz Exports?
Cipla Limited's average Efavirenz shipment value is $50.0K per consignment, based on 59 shipments totaling $3.0M. The largest destination is COLOMBIA (29.1% of Cipla Limited's Efavirenz exports).
How Does Cipla Limited Compare to Other Indian Efavirenz Exporters?
Cipla Limited ranks #3 among 101 Indian Efavirenz exporters with a 5.4% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($8.3M), MACLEODS PHARMACEUTICALS LTD ($6.0M), CIPLA LIMITED ($3.0M). Cipla Limited processed 59 shipments to 12 destination countries.
What Efavirenz Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| TENOMUNE 300/200/600 TABLETS (EFAVIRENZ | $200.0K | 4 |
| TENOMUNE 300/200/600 TABLETS (EFAVIRENZ 600 MG,EMTRICITABINE 200MG AND TENOFOVIR DISOPROXIL FUMARATE 300 MG)( | $150.0K | 3 |
| VIRADAY TAB. (EFAVIRENZ 600 MG+EMTRICIIN | $136.5K | 3 |
| Efavirenz Tablets USP 600 mg NDC No. 6 | $100.0K | 2 |
| TENOMUNE 300/200/600 TABLETS EFAVIRENZ | $100.0K | 2 |
| TENOMUNE 300/200/600 TABLETS (EFAVIRENZ600 MG, EMTRICITABINE 200 MG AND TENOFOVIR DISOPROXIL FUMARATE 300 MG) (INV.QTY | $75.8K | 2 |
| VIRADAY TAB (EFAVIRENZ 600MG+EMTRICIINE200MG+TENOFOVIR DISOPROXIL FUMARATE 300MG ) (2730 PACKS X 1X30S=81900 NOS)NOS | $70.9K | 3 |
| EFAVIR 200 CAPSULES (EFAVIRENZ 200MG) (Q | $64.3K | 2 |
| VIRADAY TAB (EFAVIRENZ 600MG+EMTRICIINE 200MG+TENOFOVIR DISOPROXIL FUMARATE 300MG) INV. QTY.1960 PACK 1X30'S= | $51.2K | 3 |
| VIRADAY-V TAB.(EFAVIRENZ600MG+EMTRICITAB | $50.0K | 1 |
Cipla Limited exports 39 distinct Efavirenz formulations including tablets, capsules, syrups, and combination drugs. The top formulation is TENOMUNE 300/200/600 TABLETS (EFAVIRENZ with 4 shipments worth $200.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Efavirenz to Key Markets
What Cipla Limited must comply with to export Efavirenz to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Efavirenz Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | MYLAN LABORATORIES LIMITED | $8.3M | 167 | 40 | $50.0K |
| 1 | MACLEODS PHARMACEUTICALS LTD | $6.0M | 121 | 33 | $50.0K |
| 3 | CIPLA LIMITED ★ | $3.0M | 59 | 12 | $50.0K |
| 4 | MACLEODS PHARMACEUTICALS LIMITED | $2.6M | 56 | 12 | $46.1K |
| 5 | HETERO LABS LIMITED | $2.0M | 49 | 19 | $40.8K |
Cipla Limited ranks #3 among 101 Indian Efavirenz exporters. Average shipment value of $50.0K compared to the market average of $264.0K. The closest competitors by value are MYLAN LABORATORIES LIMITED and MACLEODS PHARMACEUTICALS LTD.
Which Indian Ports Ship Efavirenz Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 244 | 22.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 196 | 18.1% |
| Bombay Air | 89 | 8.2% |
| DELHI AIR CARGO ACC (INDEL4) | 73 | 6.7% |
| DELHI AIR | 64 | 5.9% |
| NHAVA SHEVA SEA (INNSA1) | 57 | 5.3% |
| JNPT/ NHAVA SHEVA SEA | 43 | 4.0% |
| BANGALORE ACC (INBLR4) | 30 | 2.8% |
Geopolitical & Trade Policy Impact on Cipla Limited's Efavirenz Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Efavirenz, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Efavirenz — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Efavirenz shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 59 individual customs records matching Cipla Limited exporting Efavirenz, covering 39 formulations to 12 countries via 20 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 121+ countries, 361+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Efavirenz Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Efavirenz exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Efavirenz Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Efavirenz. For current shipment-level data, contact TransData Nexus.